<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Sampling the model parameters • iviRA</title>
<!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.3.1/jquery.min.js" integrity="sha256-FgpCb/KJQlLNfOu91ta32o/NMZxltwRo8QtmkMRdAu8=" crossorigin="anonymous"></script><!-- Bootstrap --><link href="https://cdnjs.cloudflare.com/ajax/libs/bootswatch/3.3.7/simplex/bootstrap.min.css" rel="stylesheet" crossorigin="anonymous">
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha256-U5ZEeKfGNOja007MMD3YBI0A3OSZOQbeG6z2f2Y0hu8=" crossorigin="anonymous"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.7.1/css/all.min.css" integrity="sha256-nAmazAk6vS34Xqo0BSrTb+abbtFlgsFK7NKSi6o7Y78=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.7.1/css/v4-shims.min.css" integrity="sha256-6qHlizsOWFskGlwVOKuns+D1nB6ssZrHQrNj1wGplHc=" crossorigin="anonymous">
<!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.4/clipboard.min.js" integrity="sha256-FiZwavyI2V6+EXO1U+xzLG3IKldpiTFf3153ea9zikQ=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.9.4/headroom.min.js" integrity="sha256-DJFC1kqIhelURkuza0AvYal5RxMtpzLjFhsnVIeuk+U=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.9.4/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script><meta property="og:title" content="Sampling the model parameters">
<meta property="og:description" content="">
<meta name="twitter:card" content="summary">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body>
    <div class="container template-article">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">iviRA</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="Released version">2.0.0</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Tutorial
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="../articles/00-intro.html">0. Introduction</a>
    </li>
    <li>
      <a href="../articles/01-population.html">1. Generate population</a>
    </li>
    <li>
      <a href="../articles/02-tx-seqs.html">2. Select treatment sequences</a>
    </li>
    <li>
      <a href="../articles/03-structures.html">3. Select model structures</a>
    </li>
    <li>
      <a href="../articles/04-input-data.html">4. Generate input data</a>
    </li>
    <li>
      <a href="../articles/05-parameters.html">5. Sample parameters</a>
    </li>
    <li>
      <a href="../articles/06-ips.html">6. Run simulation</a>
    </li>
    <li>
      <a href="../articles/07-analysis.html">7. Value assessment</a>
    </li>
  </ul>
</li>
<li>
  <a href="../reference/index.html">API</a>
</li>
<li>
  <a href="../articles/how-to-contribute.html">Collaborate</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    About
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="http://www.thevalueinitiative.org/open-source-value-project/">OSVP</a>
    </li>
    <li>
      <a href="../model-description/model-description.pdf">Model description</a>
    </li>
    <li>
      <a href="../news/index.html">Release history</a>
    </li>
    <li>
      <a href="../articles/reproducibility.html">Reproducibility</a>
    </li>
    <li>
      <a href="../articles/hesim.html">hesim</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Web apps
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="https://ivi-ra-expert.clarityviz.com/">IVI-RA Model Interface</a>
    </li>
    <li>
      <a href="https://ivi-ra.clarityviz.com/">IVI-RA Value Tool</a>
    </li>
  </ul>
</li>
      </ul>
<ul class="nav navbar-nav navbar-right">
<li>
  <a href="https://github.com/InnovationValueInitiative/IVI-RA">
    <span class="fab fa fab fa-github fa-lg"></span>
     
  </a>
</li>
      </ul>
</div>
<!--/.nav-collapse -->
  </div>
<!--/.container -->
</div>
<!--/.navbar -->

      

      </header><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header toc-ignore">
      <h1>Sampling the model parameters</h1>
            
      
      <small class="dont-index">Source: <a href="https://github.com/InnovationValueInitiative/IVI-RA/blob/master/vignettes/05-parameters.Rmd"><code>vignettes/05-parameters.Rmd</code></a></small>
      <div class="hidden name"><code>05-parameters.Rmd</code></div>

    </div>

    
    
<p>The <code>iviRA</code> package does not allow users to run the IPS with parameters set to fixed values, but instead recognizes that parameter values are inherently uncertain. As such, all parameters are randomly sampled from their (joint) probability distribution and the IPS is run for each randomly sampled parameter set. The parameters are sampled using the function <code>sample_pars</code>, which generates a probability distribution for all model parameters.</p>
<p>The random samples depend on the underlying statistical estimates of the distribution of the parameters. We can generate a sample of size 100 using default values.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">parsamp &lt;-<span class="st"> </span><span class="kw"><a href="../reference/sample_pars.html">sample_pars</a></span>(<span class="dt">n =</span> <span class="dv">100</span>, <span class="dt">input_data =</span> input.dat)</code></pre></div>
<p>The object <code>parsamp</code> returned from <code>sample_pars</code> is a list of random draws of the parameters used in the IPS.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/base/names.html">names</a></span>(parsamp)</code></pre></div>
<pre><code>##  [1] "n"                 "acr"               "das28"            
##  [4] "haq"               "acr2haq"           "acr2das28"        
##  [7] "acr2sdai"          "acr2cdai"          "acr2eular"        
## [10] "eular2haq"         "rebound"           "haq.lprog.tx"     
## [13] "haq.lprog.age"     "haq.lcgm"          "lt"               
## [16] "mort.logor"        "mort.loghr.haqdif" "ttd.all"          
## [19] "ttd.da"            "ttd.eular"         "ttsi"             
## [22] "tx.cost"           "hosp.cost"         "mgmt.cost"        
## [25] "si.cost"           "utility.mixture"   "utility.wailoo"   
## [28] "si.ul"             "utility.tx.attr"   "prod.loss"</code></pre>
<p>The number of samples is also returned for convenience.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">parsamp<span class="op">$</span>n</code></pre></div>
<pre><code>## [1] 100</code></pre>
<p>Users can generate samples with <code>iviRA</code> defaults or feed custom inputs into <code>sample_pars</code>. For example, we can generate a sample in which the cost of a serious infection is $7,000 instead of its default value of $5,873.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">parsamp2 &lt;-<span class="st"> </span><span class="kw"><a href="../reference/sample_pars.html">sample_pars</a></span>(<span class="dt">n =</span> <span class="dv">100</span>, <span class="dt">input_data =</span> input.dat, <span class="dt">si_cost =</span> <span class="dv">7000</span>)
<span class="kw"><a href="https://rdrr.io/r/base/summary.html">summary</a></span>(parsamp2<span class="op">$</span>si.cost)</code></pre></div>
<pre><code>##    Min. 1st Qu.  Median    Mean 3rd Qu.    Max. 
##    5608    6581    7296    7175    7838    8394</code></pre>
<p>To view the full list of arguments in <code>sample_pars</code> that can changed by the user view the documentation by typing <code><a href="../reference/sample_pars.html">?sample_pars</a></code>. All default arguments are loaded with the package and are based on IVI’s statistical estimates and synthesis of the literature. The parameter estimates can be viewed by typing the command <code><a href="https://rdrr.io/r/utils/data.html">data(package = "iviRA")</a></code> into the R console.</p>
<p>Below we describe these parameter estimates and separate them into 8 main categories: treatment effects estimated from a network meta-analysis (NMA); mappings between various measured of treatment response, disease activity, and/or function; long-term progression of disease, treatment duration, serious infections, mortality, utility, and costs.</p>
<div id="treatment-effects-during-initial-6-month-period" class="section level2">
<h2 class="hasAnchor">
<a href="#treatment-effects-during-initial-6-month-period" class="anchor"></a>Treatment effects during initial 6 month period</h2>
<p>The effect of treatment on ACR response at 6 months, change in DAS28 at 6 months, and the change in the HAQ score at 6 months are estimated using a NMA. Default NMA parameter estimates are based on results from an NMA conduced by IVI using a Bayesian random effects approach. Each object is a list containing the mean and variance-covariance matrix of the posterior distribution of the parameters.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/base/names.html">names</a></span>(iviRA<span class="op">::</span>nma.acr.naive)</code></pre></div>
<pre><code>## [1] "mean" "vcov"</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>nma.acr.naive<span class="op">$</span>mean</code></pre></div>
<pre><code>##                A               z1               z2               z3 
##        0.5499991        0.0000000        0.6231056        1.2020253 
##        d_cdmards       d_abtivmtx       d_abtscmtx         d_adamtx 
##        0.0000000       -0.9007627       -0.9005787       -0.7743447 
##            d_ada d_adabiosbwwdmtx         d_anamtx            d_bct 
##       -0.5470945       -0.7678458       -0.4505512       -0.8477756 
##         d_bctmtx            d_czp         d_czpmtx            d_etn 
##       -0.6992776       -0.7559150       -1.1912514       -0.7941323 
##         d_etnmtx d_etnbiosszzsmtx d_etnbiosykromtx            d_gol 
##       -0.7628515       -0.5468121       -0.8449216               NA 
##         d_golmtx         d_ifxmtx d_ifxbiosqbtxmtx        d_placebo 
##       -0.8450899       -0.7734014               NA        0.3774837 
##            d_nbt            d_rtx         d_rtxmtx            d_sar 
##        0.0000000       -0.5237583       -0.7040334       -0.9321168 
##         d_sarmtx         d_triple            d_tcz         d_tczmtx 
##       -0.8696777       -0.5961814       -1.0482577       -0.9883258 
##         d_tofmtx            d_tof         d_upamtx 
##       -0.7667502       -0.5347355       -0.7271539</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>nma.das28.naive<span class="op">$</span>mean</code></pre></div>
<pre><code>##                A        d_cdmards       d_abtivmtx       d_abtscmtx 
##       -0.9906912        0.0000000       -1.3419370       -1.2905265 
##         d_adamtx            d_ada d_adabiosbwwdmtx         d_anamtx 
##       -1.1957996       -0.3846224       -1.2555142               NA 
##            d_bct         d_bctmtx            d_czp         d_czpmtx 
##               NA               NA               NA       -2.0094080 
##            d_etn         d_etnmtx d_etnbiosszzsmtx d_etnbiosykromtx 
##       -1.5127713       -1.5699353       -1.5696227       -1.6663967 
##            d_gol         d_golmtx         d_ifxmtx d_ifxbiosqbtxmtx 
##               NA       -1.4525273       -0.9384479               NA 
##        d_placebo            d_nbt            d_rtx         d_rtxmtx 
##        0.4588825        0.0000000       -0.7546151       -0.9851809 
##            d_sar         d_sarmtx         d_triple            d_tcz 
##       -1.2770095               NA       -1.3012420       -1.7762413 
##         d_tczmtx         d_tofmtx            d_tof         d_upamtx 
##       -1.9362256       -0.9513472       -0.7044028       -1.2288702</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>nma.haq.naive<span class="op">$</span>mean</code></pre></div>
<pre><code>##                A        d_cdmards       d_abtivmtx       d_abtscmtx 
##       -0.2328891        0.0000000       -0.2317792       -0.2229830 
##         d_adamtx            d_ada d_adabiosbwwdmtx         d_anamtx 
##       -0.3204838       -0.1601882               NA       -0.1104685 
##            d_bct         d_bctmtx            d_czp         d_czpmtx 
##               NA               NA       -0.3193571       -0.3883754 
##            d_etn         d_etnmtx d_etnbiosszzsmtx d_etnbiosykromtx 
##       -0.1512577       -0.3369290               NA       -0.2390994 
##            d_gol         d_golmtx         d_ifxmtx d_ifxbiosqbtxmtx 
##               NA       -0.3436631       -0.2168854       -0.2400438 
##        d_placebo            d_nbt            d_rtx         d_rtxmtx 
##        0.1710748        0.0000000               NA       -0.2510926 
##            d_sar         d_sarmtx         d_triple            d_tcz 
##       -0.3404208       -0.2506528       -0.2673432       -0.2480185 
##         d_tczmtx         d_tofmtx            d_tof         d_upamtx 
##       -0.2386515       -0.4050463       -0.3117164       -0.3516575</code></pre>
<p>In the PSA, we use a multivariate normal distribution to sample the NMA parameters. The advantage of this approach is that we do not have to load the entire posterior distribution with the package. The justification is the Bayesian central limit theorem, which states that under large samples, the posterior distribution will approach a multivariate normal distribution.</p>
</div>
<div id="treatment-response-mappings" class="section level2">
<h2 class="hasAnchor">
<a href="#treatment-response-mappings" class="anchor"></a>Treatment response mappings</h2>
<p>There are various mapping between treatment response measures, disease activity, and functional status that can be used within the IVI-RA model. The exact mapping utilized for a given model run will depend on the model structure select.</p>
<p>The first set of mappings relates ACR response to the three measure of disease activity. The ACR response to SDAI mapping can either be based on the Leflunomide dataset or the inception cohort (see <a href="http://www.clinexprheumatol.org/article.asp?a=2694">Aletaha and Smolen</a>) while mapping for DAS28 and CDAI can only be based on the inception cohort. The mappings correspond to model structures where <code>itreat_switch =  "acr-das28-switch"</code>, <code>itreat_switch = "acr-sdai-switch"</code>, and <code>itreat_switch = "acr-cdai-switch"</code>. Here, we show parameters estimated from the inception cohort.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>acr2das28<span class="op">$</span>inception</code></pre></div>
<pre><code>##          acr      mean     lower     upper
## 1:  ACR &lt; 20  0.000000  0.000000  0.000000
## 2: ACR 20-50 -1.550000 -1.860000 -1.240000
## 3: ACR 50-70 -1.542727 -1.851273 -1.234182
## 4:   ACR 70+ -3.310000 -3.972000 -2.648000</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>acr2sdai<span class="op">$</span>inception</code></pre></div>
<pre><code>##          acr      mean     lower     upper
## 1:  ACR &lt; 20   0.00000   0.00000   0.00000
## 2: ACR 20-50 -13.70000 -16.44000 -10.96000
## 3: ACR 50-70 -14.88182 -17.85818 -11.90545
## 4:   ACR 70+ -30.10000 -36.12000 -24.08000</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>acr2cdai<span class="op">$</span>inception</code></pre></div>
<pre><code>##          acr      mean     lower     upper
## 1:  ACR &lt; 20   0.00000   0.00000   0.00000
## 2: ACR 20-50 -11.30000 -13.56000  -9.04000
## 3: ACR 50-70 -12.87273 -15.44727 -10.29818
## 4:   ACR 70+ -27.60000 -33.12000 -22.08000</code></pre>
<p>The relationship between ACR response and HAQ is used when a model structure uses <code>itreat_haq = "acr-haq"</code>. Evidence on mean HAQ by ACR response category is based on evidence reported in <a href="https://www.ncbi.nlm.nih.gov/pubmed/25773552">Carlson 2015</a>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>acr2haq</code></pre></div>
<pre><code>##          acr  mean      se
## 1:  ACR &lt; 20 -0.11 0.06765
## 2: ACR 20-50 -0.44 0.05657
## 3: ACR 50-70 -0.76 0.09059
## 4:   ACR 70+ -1.07 0.07489</code></pre>
<p>When <code>itreat_haq = "acr-eular-haq"</code> is selected, the model must simulate the relationship between ACR response and EULAR response. The estimated relationship is based on the number of patients in each ACR response category for a given EULAR response category in the Veterans Affairs Rheumatoid Arthritis (VARA) database as reported in the <a href="https://www.journalslibrary.nihr.ac.uk/hta/hta20350/#/s1">2016 NICE health technology assessment (HTA)</a>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>acr2eular</code></pre></div>
<pre><code>##           eular_none eular_moderate eular_good
## ACR &lt; 20         755            136         57
## ACR 20-50          4             27         26
## ACR 50-70          2              2         10
## ACR 70+            0              2          2</code></pre>
<p>When the <strong>H2</strong> pathway is used, the change in HAQ at 6 months must be simulated after EULAR response is simulated. We base this relationship on statistical analysis of the British Society for Rheumatology Biologics Register (BSRBR) data by <a href="https://www.journalslibrary.nihr.ac.uk/hta/hta20350/#/s1">NICE (2016)</a>. In particular, the 2016 NICE HTA reported mean changes in HAQ by EULAR response category at 6 months for all patients.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>eular2haq</code></pre></div>
<pre><code>##       eular   mean    se
## 1:     None  0.000 0.000
## 2: Moderate -0.317 0.048
## 3:     Good -0.672 0.112</code></pre>
</div>
<div id="long-term-haq-progression" class="section level2">
<h2 class="hasAnchor">
<a href="#long-term-haq-progression" class="anchor"></a>Long-term HAQ progression</h2>
<p>The progression of HAQ over time is modeled in two ways: first, assuming a constant annual rate, and second, by using a LCGM. The LCGM can currently only be used to model progression in the absence of tDMARDs while a constant annual rate can be used for all treatments.</p>
<p>The constant annual rate of progression for patients on cDMARDs (and NBT) are based on <a href="https://arthritis-research.biomedcentral.com/articles/10.1186/ar2944">Wolfe and Michaud’s (2010)</a> analysis of 3,829 RA patients who switched from non-biologic treatment to biologic treatment and participated in the National Data Bank for Rheumatic Diseases (NDB). The progression rate for patients on biologics are based on treatment-specific rates from <a href="http://onlinelibrary.wiley.com/doi/10.1002/acr.20405/full">Michaud et al. (2011)</a> adjusted for baseline HAQ score, age, sex, education, smoking, BMI, comorbidity, and RA onset. Importantly, The average HAQ rate among patients on a biologic was -0.001 in the Michaud et al. analysis, which instills confidence that the reported HAQ progression rates for different bDMARDs can be directly compared with the overall annual HAQ progression rate of 0.031 reported in the 2010 Wolfe and Michaud analysis.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>haq.lprog<span class="op">$</span>tx</code></pre></div>
<pre><code>##              sname    est          se   lower  upper
##  1:        cdmards  0.031 0.002551067  0.0260 0.0360
##  2:       abtivmtx -0.001 0.001530640 -0.0040 0.0020
##  3:       abtscmtx -0.001 0.001530640 -0.0040 0.0020
##  4:         adamtx -0.003 0.007398095 -0.0175 0.0115
##  5:            ada  0.012 0.006887882 -0.0015 0.0255
##  6: adabiosbwwdmtx -0.003 0.007398095 -0.0175 0.0115
##  7:         anamtx -0.001 0.001530640 -0.0040 0.0020
##  8:            bct -0.001 0.001530640 -0.0040 0.0020
##  9:         bctmtx -0.001 0.001530640 -0.0040 0.0020
## 10:            czp -0.001 0.001530640 -0.0040 0.0020
## 11:         czpmtx -0.001 0.001530640 -0.0040 0.0020
## 12:            etn -0.003 0.003826601 -0.0105 0.0045
## 13:         etnmtx -0.005 0.003316387 -0.0115 0.0015
## 14: etnbiosszzsmtx -0.005 0.003316387 -0.0115 0.0015
## 15: etnbiosykromtx -0.005 0.003316387 -0.0115 0.0015
## 16:            gol -0.001 0.001530640 -0.0040 0.0020
## 17:         golmtx -0.001 0.001530640 -0.0040 0.0020
## 18:         ifxmtx -0.001 0.003571494 -0.0080 0.0060
## 19: ifxbiosqbtxmtx -0.001 0.003571494 -0.0080 0.0060
## 20:        placebo  0.031 0.002551067  0.0260 0.0360
## 21:            nbt  0.031 0.002551067  0.0260 0.0360
## 22:            rtx -0.001 0.001530640 -0.0040 0.0020
## 23:         rtxmtx -0.001 0.001530640 -0.0040 0.0020
## 24:            sar -0.001 0.001530640 -0.0040 0.0020
## 25:         sarmtx -0.001 0.001530640 -0.0040 0.0020
## 26:         triple -0.001 0.001530640 -0.0040 0.0020
## 27:            tcz -0.001 0.001530640 -0.0040 0.0020
## 28:         tczmtx -0.001 0.001530640 -0.0040 0.0020
## 29:         tofmtx -0.001 0.001530640 -0.0040 0.0020
## 30:            tof -0.001 0.001530640 -0.0040 0.0020
## 31:         upamtx -0.001 0.001530640 -0.0040 0.0020
##              sname    est          se   lower  upper</code></pre>
<p>The constant annual rate of HAQ progression is also adjusted by age based on differences between overall and age specific rates as reported by Michaud et al. (2011).</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>haq.lprog<span class="op">$</span>diff.age</code></pre></div>
<pre><code>##       age    est          se       lower       upper
## 1:   &lt; 40 -0.020 0.004152837 -0.02813941 -0.01186059
## 2:  40-64 -0.008 0.001082326 -0.01012132 -0.00587868
## 3:  &gt;= 65  0.017 0.002179633  0.01272800  0.02127200</code></pre>
<p>The LCGM is based on the analysis by <a href="http://www.sciencedirect.com/science/article/pii/S0049017214000730">Norton et al. (2014)</a>. The parameters from the LCGM are contained in the list <code><a href="../reference/haq.lcgm.html">iviRA::haq.lcgm</a></code>. The coefficient estimates are stored in <code>iviRA::haq.lcgm$coef</code>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>haq.lcgm<span class="op">$</span>coef</code></pre></div>
<pre><code>##                    var data parameter         est    se
##  1:        intercept_1 eras     beta1   0.6377896 0.058
##  2:           linear_1 eras     beta1  -1.0086461 0.074
##  3:        quadratic_1 eras     beta1  -0.6493539 0.027
##  4:            cubic_1 eras     beta1   1.3547476 0.003
##  5:        intercept_2 eras     beta2   0.9503192 0.058
##  6:           linear_2 eras     beta2  -0.1091174 0.020
##  7:        quadratic_2 eras     beta2  -3.3681108 0.002
##  8:            cubic_2 eras     beta2   3.6994158 0.064
##  9:        intercept_3 eras     beta3   1.2652436 0.064
## 10:           linear_3 eras     beta3  -0.1316658 0.056
## 11:        quadratic_3 eras     beta3  -2.5311796 0.021
## 12:            cubic_3 eras     beta3   3.5376129 0.002
## 13:        intercept_4 eras     beta4   1.9347732 0.063
## 14:           linear_4 eras     beta4  -0.5398728 0.073
## 15:        quadratic_4 eras     beta4   1.1961146 0.027
## 16:            cubic_4 eras     beta4  -0.1087785 0.003
## 17:         constant_2 eras    delta2  -3.4960000 0.622
## 18:              age_2 eras    delta2   0.0250000 0.007
## 19:           female_2 eras    delta2   0.8410000 0.196
## 20:            das28_2 eras    delta2   0.3040000 0.080
## 21: disease_duration_2 eras    delta2   0.0320000 0.016
## 22:     rheum_factor_2 eras    delta2   0.2140000 0.237
## 23:     acr_criteria_2 eras    delta2   0.2780000 0.225
## 24:            imdq4_2 eras    delta2   0.9930000 0.366
## 25:         constant_3 eras    delta3  -6.6860000 0.660
## 26:              age_3 eras    delta3   0.0370000 0.007
## 27:           female_3 eras    delta3   1.6940000 0.214
## 28:            das28_3 eras    delta3   0.5730000 0.076
## 29: disease_duration_3 eras    delta3   0.0460000 0.017
## 30:     rheum_factor_3 eras    delta3   0.3150000 0.250
## 31:     acr_criteria_3 eras    delta3   0.4130000 0.236
## 32:            imdq4_3 eras    delta3   1.1190000 0.342
## 33:         constant_4 eras    delta4 -12.0550000 1.102
## 34:              age_4 eras    delta4   0.0820000 0.011
## 35:           female_4 eras    delta4   1.9760000 0.269
## 36:            das28_4 eras    delta4   0.8000000 0.086
## 37: disease_duration_4 eras    delta4   0.0420000 0.021
## 38:     rheum_factor_4 eras    delta4   0.2980000 0.290
## 39:     acr_criteria_4 eras    delta4   0.9390000 0.316
## 40:            imdq4_4 eras    delta4   1.4290000 0.381
##                    var data parameter         est    se</code></pre>
<p>The coefficient vectors <code>beta1</code>, <code>beta2</code>, <code>beta3</code>, and <code>beta4</code>, contain coefficients from a third order polynomial regression predicting the growth of the HAQ score over time for members of class 1, 2, 3, and 4, respectively; <code>delta2</code>, <code>delta3</code>, and <code>delta4</code> are coefficient vectors containing predictors of membership in classes 2-4 with class 1 being the reference group. A variance-covariance matrix, <code>iviRA::haq.lcgm$vcov</code>, is used to sample parameters from a multivariate normal distribution. The indices of the parameters of the variance-covariance matrix correspond to the row numbers in <code>iviRA::haq.lcgm$coef</code>.</p>
</div>
<div id="time-to-treatment-discontinuation" class="section level2">
<h2 class="hasAnchor">
<a href="#time-to-treatment-discontinuation" class="anchor"></a>Time to treatment discontinuation</h2>
<p>Time to treatment discontinuation depends on the pathway (<strong>S1-S6</strong>) used to model treatment switching. If <strong>S1</strong> is selected, a single treatment discontinuation curve is used for all patients. The parameters needed to simulate this curve are stored in. In <strong>S2-S5</strong>, time to treatment discontinuation is stratified by the level of disease activity, and in <strong>S6</strong> treatment duration depends on EULAR response (st. The parameters used to simulate treatment duration based on <strong>S1</strong>, <strong>S2-S5</strong>, and <strong>S6</strong> are stored in <code><a href="../reference/ttd.html">iviRA::ttd.all</a></code>, <code><a href="../reference/ttd.html">iviRA::ttd.da</a></code>, and <code><a href="../reference/ttd.html">iviRA::ttd.eular</a></code>, respectively.</p>
<p>The treatment duration curves are estimated using parametric survival models with the <code>flexsurv</code> package. Parameters from the survival analyses used in the IVI-RA model are stored in two-level lists. The names in the first level correspond to the name of the parametric survival model.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/base/names.html">names</a></span>(iviRA<span class="op">::</span>ttd.all)</code></pre></div>
<pre><code>## [1] "exponential" "weibull"     "gompertz"    "gamma"       "llogis"     
## [6] "lnorm"       "gengamma"</code></pre>
<p>7 parametric distributions are currently supported including the exponential, Weibull, Gompertz, gamma, log-logistic, lognormal, and generalized gamma distributions. The parameter of the survival model are stored in the second level of the list. For example, we can examine results from a Weibull fit.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/base/names.html">names</a></span>(iviRA<span class="op">::</span>ttd.all<span class="op">$</span>weibull)</code></pre></div>
<pre><code>## [1] "est"        "vcov"       "loc.index"  "anc1.index" "anc2.index"</code></pre>
<p>Point estimates are stored in the element <code>est</code> and the variance-covariance matrix is stored in the element <code>vcov</code>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>ttd.all<span class="op">$</span>weibull<span class="op">$</span>est</code></pre></div>
<pre><code>##      shape      scale 
## -0.1028306  3.7576710</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>ttd.all<span class="op">$</span>weibull<span class="op">$</span>vcov</code></pre></div>
<pre><code>##               shape         scale
## shape  1.871894e-04 -5.220527e-05
## scale -5.220527e-05  3.644134e-04</code></pre>
<p>The parametric distributions are characterized according to a location parameter governing the mean of the distribution. Models can also contain ancillary parameters which describe the shape, variance, or higher moments of a distribution. The location and ancillary parameters associated with each distribution are shown in the table below.</p>
<table class="table">
<thead><tr class="header">
<th></th>
<th align="left">Distribution</th>
<th align="left">Location</th>
<th align="left">Ancillary 1</th>
<th align="left">Ancillary 2</th>
<th align="left">iviRA name</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>exp</td>
<td align="left">Exponential</td>
<td align="left">rate</td>
<td align="left">-</td>
<td align="left">-</td>
<td align="left">exponential</td>
</tr>
<tr class="even">
<td>weibull</td>
<td align="left">Weibull</td>
<td align="left">scale</td>
<td align="left">shape</td>
<td align="left">-</td>
<td align="left">weibull</td>
</tr>
<tr class="odd">
<td>gompertz</td>
<td align="left">Gompertz</td>
<td align="left">rate</td>
<td align="left">shape</td>
<td align="left">-</td>
<td align="left">gompertz</td>
</tr>
<tr class="even">
<td>gamma</td>
<td align="left">Gamma</td>
<td align="left">rate</td>
<td align="left">shape</td>
<td align="left">-</td>
<td align="left">gamma</td>
</tr>
<tr class="odd">
<td>llogis</td>
<td align="left">Log-logistic</td>
<td align="left">scale</td>
<td align="left">shape</td>
<td align="left">-</td>
<td align="left">llogis</td>
</tr>
<tr class="even">
<td>lnorm</td>
<td align="left">Lognormal</td>
<td align="left">meanlog</td>
<td align="left">sdlog</td>
<td align="left">-</td>
<td align="left">lnorm</td>
</tr>
<tr class="odd">
<td>gengamma</td>
<td align="left">Generalized gamma</td>
<td align="left">mu</td>
<td align="left">sigma</td>
<td align="left">Q</td>
<td align="left">gengamma</td>
</tr>
</tbody>
</table>
<p>The <code>iviRA</code> package currently only allows for models in which the location parameter, but not the ancillary parameters, depends on covariates. The indices of the location parameter, first ancillary parameter, and second ancillary parameter in the <code>est</code> and <code>vcov</code> objects are contained in the <code>loc.index</code>, <code>anc1.index</code>, and <code>anc2.index</code> objects, respectively. For example, in a regression model with no covariates, the index of the location parameter is 2 and the index of the first ancillary parameter is 1.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>ttd.all<span class="op">$</span>weibull<span class="op">$</span>loc.index</code></pre></div>
<pre><code>## [1] 2</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>ttd.all<span class="op">$</span>weibull<span class="op">$</span>anc1.index</code></pre></div>
<pre><code>## [1] 1</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>ttd.all<span class="op">$</span>weibull<span class="op">$</span>anc2.index</code></pre></div>
<pre><code>## [1] NA</code></pre>
</div>
<div id="serious-infections" class="section level2">
<h2 class="hasAnchor">
<a href="#serious-infections" class="anchor"></a>Serious infections</h2>
<p>Serious infection rates are based on the NMA and Cochrane review by <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008794/full">Singh et al. (2011)</a>. In accordance with the 2016 NICE report we assume a constant serious infection rate of 0.026 for patients using cDMARDs and a constant rate of <code><a href="https://rdrr.io/r/base/Log.html">exp(iviRA::ttsi[sname == "etnmtx", lograte])</a></code> for patient using tDMARDs. A such we constantly assume that the time to a serious infection is exponentially distributed and that it does not vary across tDMARDs.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>ttsi</code></pre></div>
<pre><code>##              sname    lograte lograte_se
##  1:        cdmards  -3.649659   0.135922
##  2:       abtivmtx  -3.352407   0.135922
##  3:       abtscmtx  -3.352407   0.135922
##  4:         adamtx  -3.352407   0.135922
##  5:            ada  -3.352407   0.135922
##  6: adabiosbwwdmtx  -3.352407   0.135922
##  7:         anamtx  -3.352407   0.135922
##  8:            bct  -3.352407   0.135922
##  9:         bctmtx  -3.352407   0.135922
## 10:            czp  -3.352407   0.135922
## 11:         czpmtx  -3.352407   0.135922
## 12:            etn  -3.352407   0.135922
## 13:         etnmtx  -3.352407   0.135922
## 14: etnbiosszzsmtx  -3.352407   0.135922
## 15: etnbiosykromtx  -3.352407   0.135922
## 16:            gol  -3.352407   0.135922
## 17:         golmtx  -3.352407   0.135922
## 18:         ifxmtx  -3.352407   0.135922
## 19: ifxbiosqbtxmtx  -3.352407   0.135922
## 20:        placebo -23.025851   0.135922
## 21:            nbt -23.025851   0.135922
## 22:            rtx  -3.352407   0.135922
## 23:         rtxmtx  -3.352407   0.135922
## 24:            sar  -3.352407   0.135922
## 25:         sarmtx  -3.352407   0.135922
## 26:         triple  -3.649659   0.135922
## 27:            tcz  -3.352407   0.135922
## 28:         tczmtx  -3.352407   0.135922
## 29:         tofmtx  -3.352407   0.135922
## 30:            tof  -3.352407   0.135922
## 31:         upamtx  -3.352407   0.135922
##              sname    lograte lograte_se</code></pre>
</div>
<div id="mortality" class="section level2">
<h2 class="hasAnchor">
<a href="#mortality" class="anchor"></a>Mortality</h2>
<p>Baseline mortality for patients without RA are based on gender-specific US life tables. More specifically, we use the probability of mortality, <code>qx</code>, between ages <span class="math inline">\(x\)</span> and <span class="math inline">\(x+1\)</span>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/utils/head.html">head</a></span>(iviRA<span class="op">::</span>lifetable.male)</code></pre></div>
<pre><code>##    age       qx     lx  dx     L      Tx   ex
## 1:   0 0.006575 100000 658 99427 7629389 76.3
## 2:   1 0.000445  99342  44 99320 7529961 75.8
## 3:   2 0.000301  99298  30 99283 7430641 74.8
## 4:   3 0.000240  99268  24 99256 7331358 73.9
## 5:   4 0.000183  99244  18 99235 7232101 72.9
## 6:   5 0.000169  99226  17 99218 7132866 71.9</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/utils/head.html">head</a></span>(iviRA<span class="op">::</span>lifetable.female)</code></pre></div>
<pre><code>##    age       qx     lx  dx     L      Tx   ex
## 1:   0 0.005516 100000 552 99514 8105137 81.1
## 2:   1 0.000382  99448  38 99429 8005623 80.5
## 3:   2 0.000225  99410  22 99399 7906193 79.5
## 4:   3 0.000175  99388  17 99379 7806794 78.5
## 5:   4 0.000151  99371  15 99363 7707415 77.6
## 6:   5 0.000132  99356  13 99349 7608052 76.6</code></pre>
<p>The probability of mortality is adjusted according to a patient’s baseline HAQ score as well as changes in the HAQ score from baseline. We use the log odds ratio of the effect of baseline HAQ on mortality of 0.798 from <a href="http://onlinelibrary.wiley.com/doi/10.1002/art.11024/full">Wolfe et al. (2003)</a>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>mort.or</code></pre></div>
<pre><code>##    var   or or_se or_lower or_upper     logor logor_lower logor_upper
## 1: haq 2.22  0.24     1.79     2.75 0.7975072   0.5822156    1.011601
##     logor_se
## 1: 0.1095391</code></pre>
<p>The effect of a change in HAQ from baseline on mortality is based on the effect of 0.25 change in the HAQ score on log hazard of mortality as reported in <a href="http://www.jrheum.org/content/39/1/54.short">Michaud et al. (2012)</a>. The log hazard ratios are stratified by time-period, as reported in the original paper.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>mort.hr.haqdif</code></pre></div>
<pre><code>##    month   hr hr_lower hr_upper     loghr loghr_lower loghr_upper
## 1:     6 1.12     1.08     1.17 0.1133287  0.07696104   0.1570037
## 2:    12 1.16     1.11     1.21 0.1484200  0.10436002   0.1906204
## 3:    24 1.16     1.10     1.21 0.1484200  0.09531018   0.1906204
## 4:    36 1.21     1.14     1.28 0.1906204  0.13102826   0.2468601
## 5:    48 1.19     1.11     1.27 0.1739533  0.10436002   0.2390169
##      loghr_se
## 1: 0.02041943
## 2: 0.02200559
## 3: 0.02431427
## 4: 0.02954948
## 5: 0.03435188</code></pre>
</div>
<div id="utility" class="section level2">
<h2 class="hasAnchor">
<a href="#utility" class="anchor"></a>Utility</h2>
<p>Two models can be used to simulate utility. If the model structure <code>utility_model = "mixure"</code> is chosen, then the <a href="https://academic.oup.com/rheumatology/article/52/5/944/1816557">Hernandez Alava et al. (2013)</a> model is used; otherwise, if <code>utility_model = "wailoo"</code>, the logistic regression equation reported in <a href="https://www.sheffield.ac.uk/polopoly_fs/1.43356!/file/AHRQ-final-report.pdf">Wailoo et al. (2006)</a> is used.</p>
<p>Point estimates (i.e., log odds ratios) and standard errors associated with each variable in the Wailoo model are available in the <code><a href="../reference/utility.wailoo.html">iviRA::utility.wailoo</a></code> object.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>utility.wailoo</code></pre></div>
<pre><code>##            var     est     se
## 1:         int  2.0734 0.0263
## 2:         age  0.0058 0.0004
## 3:     dis_dur  0.0023 0.0004
## 4:        haq0 -0.2004 0.0101
## 5:        male -0.2914 0.0118
## 6: prev_dmards  0.0249 0.0028
## 7:         haq -0.8647 0.0103</code></pre>
<p>The information needed to sample from the mixture model are stored in the list <code><a href="../reference/utility.mixture.html">iviRA::utility.mixture</a></code>. The setup is the same as with the LCGM in that the list contains a table of coefficient estimates as well as the corresponding variance covariance matrix.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/base/names.html">names</a></span>(iviRA<span class="op">::</span>utility.mixture)</code></pre></div>
<pre><code>## [1] "coef" "vcov"</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>utility.mixture<span class="op">$</span>coef</code></pre></div>
<pre><code>##            var parameter           est
## 1          HAQ     beta1  -0.089819885
## 2         HAQ2     beta1   0.000525916
## 3     Pain/100     beta1  -0.057952582
## 4      Age/10m     beta1   0.004871839
## 5     Age/10m2     beta1   0.000277046
## 6          HAQ     beta2   0.054383137
## 7         HAQ2     beta2  -0.050915914
## 8     Pain/100     beta2  -0.384088121
## 9      Age/10m     beta2   0.029093294
## 10    Age/10m2     beta2   0.002262836
## 11         HAQ     beta3  -0.141482101
## 12        HAQ2     beta3   0.015465378
## 13    Pain/100     beta3  -0.083925893
## 14     Age/10m     beta3   0.003728168
## 15    Age/10m2     beta3   0.000718860
## 16         HAQ     beta4  -0.195798978
## 17        HAQ2     beta4   0.034715726
## 18    Pain/100     beta4  -0.012745796
## 19     Age/10m     beta4  -0.004299891
## 20    Age/10m2     beta4   0.000227100
## 21  Intercept1    alpha1   0.814127363
## 22  Intercept2    alpha2   0.426581217
## 23  Intercept3    alpha3   0.329688793
## 24  Intercept4    alpha4   1.022019574
## 25        Male     alpha  -0.026542757
## 26  Variance 1  epsilon1   0.002517113
## 27  Variance 2  epsilon2   0.023997163
## 28  Variance 3  epsilon3   0.002224878
## 29  Variance 4  epsilon4   0.004379523
## 30    Variance        mu   0.002605149
## 31 Intercept 1    delta1  -1.274627693
## 32         HAQ    delta1   0.242049855
## 33    Pain/100    delta1  23.467307110
## 34   Pain/1002    delta1 -21.551251860
## 35 Intercept 2    delta2  -6.631010968
## 36         HAQ    delta2   2.193565335
## 37    Pain/100    delta2  18.371864330
## 38   Pain/1002    delta2 -13.800080430
## 39 Intercept 3    delta3  -7.476836039
## 40         HAQ    delta3   1.051656593
## 41    Pain/100    delta3  25.339552780
## 42   Pain/1002    delta3 -16.962219250</code></pre>
<p>Quality-adjusted life-years are also decreased in each period that there is a serious infection and is assumed to vary by 20 percent in either direction.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/base/formals.html">formals</a></span>(sample_pars)<span class="op">$</span>si_ul</code></pre></div>
<pre><code>## [1] 0.156</code></pre>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/base/formals.html">formals</a></span>(sample_pars)<span class="op">$</span>si_ul_range</code></pre></div>
<pre><code>## [1] 0.2</code></pre>
</div>
<div id="costs" class="section level2">
<h2 class="hasAnchor">
<a href="#costs" class="anchor"></a>Costs</h2>
<p>The model incorporates 3 main types of health care sector costs: (1) drug acquisition and administration costs, (2) hospitalization costs, and (3) general management costs. Productivity losses can also be included in the analysis if the analyst would like to take a societal perspective.</p>
<div id="treatment-costs" class="section level3">
<h3 class="hasAnchor">
<a href="#treatment-costs" class="anchor"></a>Treatment costs</h3>
<p>Drug acquisition and administration costs are separated into costs associated with the first 6 months of treatment and costs after the first 6 months. Costs are a function of the FDA recommended dose and frequency of administration, strength and dosage form, the price, and infusion. Prices with the simulation are reduced according to assumed discounts and rebates. If dosing is weight based, then the dose is calculated by multiplying the dose value (e.g., <code>init_dose_val</code> and <code>ann_dose_val</code>) by each patients weight in kilograms; otherwise the dose is simply equal to the dose value. For example, the dose for infliximab during the first six months is equal to 3 multiplied by the weight of the patient.</p>
<p>Information related to treatment costs are stored in the list <code><a href="../reference/tx.cost.html">iviRA::tx.cost</a></code>. Data related to the costs of treatment for each medication are in the data table <code>iviRA::tx.cost$cost</code>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r"><span class="kw"><a href="https://rdrr.io/r/base/library.html">library</a></span>(knitr)
<span class="kw"><a href="https://rdrr.io/pkg/knitr/man/kable.html">kable</a></span>(iviRA<span class="op">::</span>tx.cost<span class="op">$</span>cost)</code></pre></div>
<table class="table">
<thead><tr class="header">
<th align="left">name</th>
<th align="left">sname</th>
<th align="left">dosage</th>
<th align="left">strength_dosage_form</th>
<th align="right">init_dose_val</th>
<th align="right">ann_dose_val</th>
<th align="left">dose_unit</th>
<th align="right">init_num_doses</th>
<th align="right">ann_num_doses</th>
<th align="right">strength_val</th>
<th align="left">strength_unit</th>
<th align="right">price_per_unit</th>
<th align="right">discount_lower</th>
<th align="right">discount_upper</th>
<th align="right">infusion_cost</th>
<th align="right">loading_dose</th>
<th align="right">weight_based</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">abatacept IV</td>
<td align="left">abtiv</td>
<td align="left">750 mg IV at weeks 0, 2, 4 then Q4W</td>
<td align="left">250mg vial</td>
<td align="right">750</td>
<td align="right">750</td>
<td align="left">mg</td>
<td align="right">8</td>
<td align="right">13.000000</td>
<td align="right">250.0</td>
<td align="left">mg</td>
<td align="right">1167.33000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">164</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">abatacept SC</td>
<td align="left">abtsc</td>
<td align="left">125 mg SC QW with IV loading dose</td>
<td align="left">125mg/ml syringe</td>
<td align="right">125</td>
<td align="right">125</td>
<td align="left">mg</td>
<td align="right">26</td>
<td align="right">52.000000</td>
<td align="right">125.0</td>
<td align="left">mg</td>
<td align="right">1094.72250</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">164</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">adalimumab</td>
<td align="left">ada</td>
<td align="left">40 mg EOW</td>
<td align="left">40 mg/0.8 mL syringe or pen injector</td>
<td align="right">40</td>
<td align="right">40</td>
<td align="left">mg</td>
<td align="right">13</td>
<td align="right">26.000000</td>
<td align="right">40.0</td>
<td align="left">mg</td>
<td align="right">2587.04500</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">adalimumab-bwwd (biosimilar Samsung Bioepis)</td>
<td align="left">adabiosbwwd</td>
<td align="left">40 mg EOW</td>
<td align="left">40 mg/0.8 mL syringe or pen injector</td>
<td align="right">40</td>
<td align="right">40</td>
<td align="left">mg</td>
<td align="right">13</td>
<td align="right">26.000000</td>
<td align="right">40.0</td>
<td align="left">mg</td>
<td align="right">2069.63600</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">anakinra</td>
<td align="left">ana</td>
<td align="left">100 mg daily</td>
<td align="left">100 mg syringe</td>
<td align="right">100</td>
<td align="right">100</td>
<td align="left">mg</td>
<td align="right">182</td>
<td align="right">364.000000</td>
<td align="right">100.0</td>
<td align="left">mg</td>
<td align="right">147.06714</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">baricitinib</td>
<td align="left">bct</td>
<td align="left">2 mg daily</td>
<td align="left">2 mg tablet</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="left">mg</td>
<td align="right">182</td>
<td align="right">364.000000</td>
<td align="right">2.0</td>
<td align="left">mg</td>
<td align="right">71.23000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">certolizumab pegol</td>
<td align="left">czp</td>
<td align="left">400 mg at weeks 0, 2, 4 then 200 mg Q2W</td>
<td align="left">400 mg kit or syringe kit (200 mg 2)</td>
<td align="right">200</td>
<td align="right">200</td>
<td align="left">mg</td>
<td align="right">16</td>
<td align="right">26.000000</td>
<td align="right">200.0</td>
<td align="left">mg</td>
<td align="right">4327.43000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">etanercept</td>
<td align="left">etn</td>
<td align="left">50 mg QW</td>
<td align="left">50 mg/0.98 mL syringe or pen injector</td>
<td align="right">50</td>
<td align="right">50</td>
<td align="left">mg</td>
<td align="right">26</td>
<td align="right">52.000000</td>
<td align="right">50.0</td>
<td align="left">mg</td>
<td align="right">1293.51500</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">etanercept-szzs (biosimilar Sandoz)</td>
<td align="left">etnbiosszzs</td>
<td align="left">50 mg QW</td>
<td align="left">50 mg/0.98 mL syringe or pen injector</td>
<td align="right">50</td>
<td align="right">50</td>
<td align="left">mg</td>
<td align="right">26</td>
<td align="right">52.000000</td>
<td align="right">50.0</td>
<td align="left">mg</td>
<td align="right">1034.81200</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">etanercept-ykro (biosimilar Samsung Bioepis)</td>
<td align="left">etnbiosykro</td>
<td align="left">50 mg QW</td>
<td align="left">50 mg/0.98 mL syringe or pen injector</td>
<td align="right">50</td>
<td align="right">50</td>
<td align="left">mg</td>
<td align="right">26</td>
<td align="right">52.000000</td>
<td align="right">50.0</td>
<td align="left">mg</td>
<td align="right">1034.81200</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">golimumab</td>
<td align="left">gol</td>
<td align="left">50 mg QM</td>
<td align="left">50 mg/0.5 mL syringe or pen injector</td>
<td align="right">50</td>
<td align="right">50</td>
<td align="left">mg</td>
<td align="right">6</td>
<td align="right">12.000000</td>
<td align="right">50.0</td>
<td align="left">mg</td>
<td align="right">4809.02000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">hydroxychloroquine sulfate</td>
<td align="left">hcl</td>
<td align="left">400 mg daily</td>
<td align="left">200 mg tablet</td>
<td align="right">400</td>
<td align="right">400</td>
<td align="left">mg</td>
<td align="right">182</td>
<td align="right">364.000000</td>
<td align="right">200.0</td>
<td align="left">mg</td>
<td align="right">3.88200</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">infliximab</td>
<td align="left">ifx</td>
<td align="left">3 mg/kg at 0, 2, and 6 weeks, 3mg/kg Q8W, 6 mg/kg Q6W after 6 months</td>
<td align="left">100 mg vial</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="left">mg/kg</td>
<td align="right">5</td>
<td align="right">8.666667</td>
<td align="right">100.0</td>
<td align="left">mg</td>
<td align="right">1167.82000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">164</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr class="even">
<td align="left">infliximab-qbtx (biosimilar Pfizer)</td>
<td align="left">ifxbiosqbtx</td>
<td align="left">3 mg/kg at 0, 2, and 6 weeks, 3mg/kg Q8W, 6 mg/kg Q6W after 6 months</td>
<td align="left">100 mg vial</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="left">mg/kg</td>
<td align="right">5</td>
<td align="right">8.666667</td>
<td align="right">100.0</td>
<td align="left">mg</td>
<td align="right">946.28000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">164</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr class="odd">
<td align="left">methotrexate</td>
<td align="left">cdmards</td>
<td align="left">15mg QW</td>
<td align="left">15 mg injection</td>
<td align="right">15</td>
<td align="right">15</td>
<td align="left">mg</td>
<td align="right">26</td>
<td align="right">52.000000</td>
<td align="right">15.0</td>
<td align="left">mg</td>
<td align="right">5.81000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">rituximab</td>
<td align="left">rtx</td>
<td align="left">1000 mg at weeks 0, 2; then Q24 W</td>
<td align="left">500 mg/50ml vial</td>
<td align="right">1000</td>
<td align="right">1000</td>
<td align="left">mg</td>
<td align="right">4</td>
<td align="right">4.333333</td>
<td align="right">500.0</td>
<td align="left">mg</td>
<td align="right">4697.60000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">164</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">sarilumab</td>
<td align="left">sar</td>
<td align="left">200 mg EOW</td>
<td align="left">200mg/1.14 mL syringe</td>
<td align="right">200</td>
<td align="right">200</td>
<td align="left">mg</td>
<td align="right">13</td>
<td align="right">26.000000</td>
<td align="right">200.0</td>
<td align="left">mg</td>
<td align="right">1457.57456</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">sulfazalazine</td>
<td align="left">ssz</td>
<td align="left">1-2 g daily</td>
<td align="left">500 mg tablet</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="left">g</td>
<td align="right">182</td>
<td align="right">364.000000</td>
<td align="right">0.5</td>
<td align="left">g</td>
<td align="right">0.24202</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">tocilizumab</td>
<td align="left">tcz</td>
<td align="left">162 mg SC EOW</td>
<td align="left">162 mg/0.9 mL syringe</td>
<td align="right">162</td>
<td align="right">162</td>
<td align="left">mg</td>
<td align="right">13</td>
<td align="right">26.000000</td>
<td align="right">162.0</td>
<td align="left">mg</td>
<td align="right">1014.26000</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">tofaticinib</td>
<td align="left">tof</td>
<td align="left">5 mg BID</td>
<td align="left">5 mg tablet</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="left">mg</td>
<td align="right">364</td>
<td align="right">728.000000</td>
<td align="right">5.0</td>
<td align="left">mg</td>
<td align="right">74.67717</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr class="odd">
<td align="left">upadacitinib</td>
<td align="left">upa</td>
<td align="left">15 mg daily</td>
<td align="left">15 mg tablet</td>
<td align="right">15</td>
<td align="right">15</td>
<td align="left">mg</td>
<td align="right">182</td>
<td align="right">364.000000</td>
<td align="right">15.0</td>
<td align="left">mg</td>
<td align="right">163.88900</td>
<td align="right">0.2</td>
<td align="right">0.3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The variable <code>init_num_doses</code> is the number of doses during the first 6 months after beginning a new treatment and the variable <code>ann_num_doses</code> is the number of doses <em>per year</em> after the first 6 months. The variables <code>discount_lower</code> and <code>discount_upper</code> are lower and upper bounds for the amount by which prices (<code>price_per_unit</code>) are decreased after discounts and rebates.</p>
<p>Costs for individual therapeutic agents are used to calculate costs for the (combination) treatments in a treatment sequence by using the lookup data table <code>iviRA::tx.cost$lookup</code>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>tx.cost<span class="op">$</span>lookup</code></pre></div>
<pre><code>##              sname      agent1  agent2
##  1:        cdmards     cdmards    &lt;NA&gt;
##  2:       abtivmtx       abtiv cdmards
##  3:       abtscmtx       abtsc cdmards
##  4:         adamtx         ada cdmards
##  5:            ada         ada    &lt;NA&gt;
##  6: adabiosbwwdmtx adabiosbwwd cdmards
##  7:         anamtx         ana cdmards
##  8:            bct         bct    &lt;NA&gt;
##  9:         bctmtx         bct cdmards
## 10:            czp         czp    &lt;NA&gt;
## 11:         czpmtx         czp cdmards
## 12:            etn         etn    &lt;NA&gt;
## 13:         etnmtx         etn cdmards
## 14: etnbiosszzsmtx etnbiosszzs cdmards
## 15: etnbiosykromtx etnbiosykro cdmards
## 16:            gol         gol    &lt;NA&gt;
## 17:         golmtx         gol cdmards
## 18:         ifxmtx         ifx cdmards
## 19: ifxbiosqbtxmtx ifxbiosqbtx cdmards
## 20:        placebo     placebo    &lt;NA&gt;
## 21:            nbt         nbt    &lt;NA&gt;
## 22:            rtx         rtx    &lt;NA&gt;
## 23:         rtxmtx         rtx cdmards
## 24:            sar         sar    &lt;NA&gt;
## 25:         sarmtx         sar cdmards
## 26:         triple         hcl cdmards
## 27:            tcz         tcz    &lt;NA&gt;
## 28:         tczmtx         tcz cdmards
## 29:         tofmtx         tof cdmards
## 30:            tof         tof    &lt;NA&gt;
## 31:         upamtx         upa cdmards
##              sname      agent1  agent2</code></pre>
<p>The treatment names in the first column (<code>sname</code>) must match the names of the treatments selected in a treatment sequence. All subsequent columns refer to the names of the therapeutic agents used for a particular treatment. For example, the treatment <code>etnmtx</code> contains both etanercept and methotrexate/conventional cDMARDs.</p>
</div>
<div id="other-health-care-sector-costs" class="section level3">
<h3 class="hasAnchor">
<a href="#other-health-care-sector-costs" class="anchor"></a>Other health care sector costs</h3>
<p>Hospitalization costs are estimated as a function of the HAQ score. In particular, <a href="https://www.ncbi.nlm.nih.gov/pubmed/25773552">Carlson 2015</a>, report estimates of the number of days in the hospital for a given HAQ score range as well as the cost of a single day in the hospital.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>hosp.cost</code></pre></div>
<pre><code>##          haq days_mean days_se cost_pday_mean cost_pday_se
## 1: 0 to &lt;0.5      0.26     0.5       1347.088     205.6705
## 2: 0.5 to &lt;1      0.13     0.5       1347.088     205.6705
## 3: 1 to &lt;1.5      0.51     0.5       1347.088     205.6705
## 4: 1.5 to &lt;2      0.72     0.5       1347.088     205.6705
## 5: 2 to &lt;2.5      1.86     0.5       1347.088     205.6705
## 6:      &gt;2.5      4.16     0.5       1347.088     205.6705</code></pre>
<p>Management costs are based on mean costs and cost ranges reported in <a href="http://www.jmcp.org/doi/full/10.18553/jmcp.2016.22.9.1088">Claxton (2016)</a>.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>mgmt.cost</code></pre></div>
<pre><code>##                service       est     lower     upper        se
## 1:          chest_xray 117.37215 104.45045 130.29386  6.592828
## 2:          xray_visit  57.07086  48.45639  65.68533  4.395218
## 3: outpatient_followup 201.36323 171.21259 231.51388 15.383265
## 4:                 tst  32.84267  32.84267  32.84267  0.000000</code></pre>
</div>
<div id="productivity-losses" class="section level3">
<h3 class="hasAnchor">
<a href="#productivity-losses" class="anchor"></a>Productivity losses</h3>
<p>We use estimates of productivity loss from <a href="http://www.jrheum.org/content/32/10/1875.short">Wolfe et al. (2005)</a>. The authors provide estimates of the annual loss in earnings associated with a 1-unit increase in HAQ, which we convert to 2017 dollars.</p>
<div class="sourceCode"><pre class="sourceCode r"><code class="sourceCode r">iviRA<span class="op">::</span>prod.loss</code></pre></div>
<pre><code>##         est       se
## 1: 6218.603 1643.376</code></pre>
<div>
<ul class="pager">
<li class="previous">
<a href="04-input-data.html">Previous</a>
</li>
<li class="next">
<a href="06-ips.html">Next</a>
</li>
</ul>
</div>
</div>
</div>
  </div>

  <div class="col-md-3 hidden-xs hidden-sm" id="sidebar">
        <div id="tocnav">
      <h2 class="hasAnchor">
<a href="#tocnav" class="anchor"></a>Contents</h2>
      <ul class="nav nav-pills nav-stacked">
<li><a href="#treatment-effects-during-initial-6-month-period">Treatment effects during initial 6 month period</a></li>
      <li><a href="#treatment-response-mappings">Treatment response mappings</a></li>
      <li><a href="#long-term-haq-progression">Long-term HAQ progression</a></li>
      <li><a href="#time-to-treatment-discontinuation">Time to treatment discontinuation</a></li>
      <li><a href="#serious-infections">Serious infections</a></li>
      <li><a href="#mortality">Mortality</a></li>
      <li><a href="#utility">Utility</a></li>
      <li><a href="#costs">Costs</a></li>
      </ul>
</div>
      </div>

</div>



      <footer><div class="copyright">
  <p>Developed by Jeroen P. Jansen, Devin Incerti.</p>
</div>

<div class="pkgdown">
  <p>Site built with <a href="https://pkgdown.r-lib.org/">pkgdown</a> 1.4.1.</p>
</div>

      </footer>
</div>

  


  </body>
</html>
